Hi Longevity Enthusiast,

There are cells inside your body that are neither functioning normally nor dead.

Scientists call them senescent cells.

You'll sometimes hear a more memorable name:

“Zombie cells.”

As we age, these cells can accumulate in our tissues.

For years, longevity researchers have been asking a seemingly obvious question:

Can we get rid of them?

But a new study published just days ago suggests there may be another possibility.

Maybe we don't always have to kill them.

Maybe we can make some of them quieter.

Normally, damaged cells can stop dividing.

That's actually protective. It can prevent damaged cells from continuing to replicate.

The problem begins when some of these cells remain behind.

They don't simply sit there doing nothing.

Many release a cocktail of inflammatory molecules known as the senescence-associated secretory phenotype, or SASP. Senescent cells and their inflammatory activity have increasingly become targets in aging research.

Think of it this way:

The cell has retired from its old job.

But it hasn't stopped sending emails to everyone in the building.

And some of those emails are inflammatory.

In the new study, researchers identified two proteins called cyclin D1 and CDK6 that appear to help drive this inflammatory behavior.

That's interesting because these proteins are better known for their role in controlling how cells divide.

But here they were doing something different.

They were helping senescent cells maintain their inflammatory state through a pathway involving DNA damage and cGAS-STING signaling.

So the researchers tried blocking the pathway.

And something remarkable happened.

The cells became quieter.

Their inflammatory gene activity decreased.

But the researchers weren't necessarily destroying the senescent cells themselves.

They were changing what those cells were doing.

Researchers used palbociclib, a drug that inhibits CDK4/6.

In aged mice, treatment reduced senescence-associated inflammatory activity and was associated with improvements in motor function and measures of frailty.

A separate Nature Aging study published this summer found a related effect using another CDK4/6 inhibitor, abemaciclib: suppressing inflammatory signals from senescent cells and improving physical performance in aged mice.

And this changes the question scientists can ask.

Instead of only:

“How do we remove aging cells?”

Researchers can also investigate:

“Can we stop aging cells from damaging the tissue around them?”

This part matters.

The exciting results are preclinical.

Improving frailty in an old mouse is very different from proving that a treatment slows human aging.

And drugs such as palbociclib and abemaciclib are real medicines with real risks - not longevity supplements to experiment with.

But the underlying discovery is fascinating.

Because one of the major ideas in longevity research has been to eliminate senescent cells using senolytics.

This research points toward another strategy:

senomorphics.

Instead of killing the zombie...

change its behavior.

Aging research is increasingly moving beyond one simple question:

What breaks as we get older?

Toward a much more interesting one:

What are aging cells doing to the cells around them?

Because sometimes the problem may not be that an old cell has stopped working.

The problem may be that it won't stop talking.

Stay curious,

David

Founder, Longevity Enthusiasts